Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP) by Seini Moimoi | Aug 19, 2019 | Portfolio News
Nabriva Therapeutics Provides Update on the Planned Resubmission of the New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection by Seini Moimoi | Aug 16, 2019 | Portfolio News
Venus Concept Announces Financial Results for the Second Quarter and First Six Months of 2019 and FDA 510(k) Clearance of Venus Bliss™ by Seini Moimoi | Aug 15, 2019 | Portfolio News
Molecular Templates, Inc. Reports Second Quarter 2019 Financial Results by Seini Moimoi | Aug 12, 2019 | Portfolio News
Aptinyx Reports Second Quarter 2019 Financial Results and Highlights by Seini Moimoi | Aug 12, 2019 | Portfolio News
